- Home
- HIFS vs RGNX Comparison
HIFS vs RGNX Comparison
Compare HIFS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIFS | RGNX |
|---|---|---|
| Founded | 1834 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.4M | 678.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | HIFS | RGNX |
|---|---|---|
| Price | $279.15 | $15.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.78 |
| AVG Volume (30 Days) | 87.7K | ★ 684.2K |
| Earning Date | 01-16-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ 94.74 | N/A |
| EPS | ★ 20.54 | N/A |
| Revenue | $90,528,000.00 | ★ $161,318,000.00 |
| Revenue This Year | N/A | $132.80 |
| Revenue Next Year | N/A | $45.32 |
| P/E Ratio | $14.70 | ★ N/A |
| Revenue Growth | 54.99 | ★ 91.30 |
| 52 Week Low | $209.71 | $5.04 |
| 52 Week High | $320.00 | $15.41 |
Technical Indicators
Market Signals| Indicator | HIFS | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 61.78 |
| Support Level | $261.25 | $12.87 |
| Resistance Level | $303.55 | $14.65 |
| Average True Range (ATR) | 14.40 | 0.95 |
| MACD | -0.66 | -0.03 |
| Stochastic Oscillator | 42.32 | 77.13 |
Price Performance
Historical ComparisonAbout HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.